SHM Converge Scientific Abstract ePoster Gallery-Remdesivir Reduces Mortality in Hospitalized Covid-19 Patients Requiring Low-Flow Oxygen

Pdf Summary

This poster reports a large retrospective U.S. comparative effectiveness study evaluating whether early remdesivir (RDV) reduces inpatient mortality in hospitalized adults with COVID-19 who required low-flow oxygen (LFO) within the first two days of admission. The study used the PINC AI Healthcare Database and included patients hospitalized from December 2020 through April 2022, spanning three variant-of-concern periods: pre-Delta, Delta, and Omicron.<br /><br />After applying inclusion and exclusion criteria, 116,012 patients on LFO were analyzed. Most received RDV early (81,811), while 34,201 did not. Propensity score matching produced well-balanced groups of 67,582 patients in each arm. The main outcomes were 14-day and 28-day all-cause inpatient mortality.<br /><br />Across the full matched cohort, RDV was associated with significantly lower mortality than no RDV, both in unadjusted Kaplan-Meier analyses and in adjusted Cox proportional hazards models. This mortality benefit was consistent across all three variant periods. The adjusted results showed lower 14-day mortality for RDV versus non-RDV patients (6.4% vs 8.8% overall) and lower 28-day mortality (9.8% vs 12.3% overall), with similar patterns in pre-Delta, Delta, and Omicron periods.<br /><br />The authors conclude that starting RDV within two days of hospital admission is linked to significant reductions in 14- and 28-day mortality among hospitalized COVID-19 patients requiring low-flow oxygen, regardless of circulating variant period. They also note that RDV had shown similar benefit in patients with higher oxygen needs in prior work. Despite guideline support and observed benefits, more than one-quarter of eligible patients did not receive RDV, suggesting room to improve use of evidence-based treatment.

Asset Subtitle

Essy Mozaffari

Meta Tag

Author List Aastha Chandak, Andre C. Kalil, Celine Der-Torossian, Chidinma Chima-Melton, Essy Mozaffari, EunYoung Lee, Heng Jiang, Mark Berry, Mark Thrun, Rikisha Gupta, Robert L. Gottlieb, Stijn Hollemeersch

Category Research

Concept Remdesivir

Concept Mortality

Concept All-cause inpatient mortality

Concept Hospitalized COVID-19 Patients

Concept Low-flow oxygen

Distinguished Non-Finalist

Presenter Organization Gilead Sciences

Presenting Author Essy Mozaffari

Track Outcomes Research

Keywords

remdesivir

COVID-19

low-flow oxygen

hospital mortality

comparative effectiveness

retrospective study

propensity score matching

variant periods

PINC AI Healthcare Database

inpatient mortality

Remdesivir

Mortality

All-cause inpatient mortality

Hospitalized COVID-19 Patients

Low-flow oxygen